FDA preps for a new and flex­i­ble ap­proach to genome edit­ing in an­i­mals

With the use of CRISPR pro­lif­er­at­ing and gene dri­ves on the hori­zon in the US, the FDA said that it’s now look­ing at a risk-based ap­proach to reg­u­lat­ing the gene edit­ing of an­i­mals.

As part of that ap­proach the agency is es­tab­lish­ing a new pi­lot pro­gram, known as the Vet­eri­nary In­no­va­tion Pro­gram (VIP). It’s charged with pro­vid­ing tech­ni­cal and pro­gram­mat­ic as­sis­tance to de­vel­op­ers seek­ing FDA ap­proval of in­ten­tion­al­ly al­tered ge­nom­ic DNA in an­i­mals and an­i­mal cells, tis­sues and cell- or tis­sue-based prod­ucts that pro­vide a ben­e­fit to hu­man health, an­i­mal health, an­i­mal well-be­ing or food pro­duc­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER